Cantor Fitzgerald Analysts Lift Earnings Estimates for HRMY

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Harmony Biosciences in a report issued on Wednesday, May 7th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn $2.68 per share for the year, up from their previous forecast of $2.43. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company’s revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS.

Several other equities analysts have also commented on HRMY. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Mizuho raised their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday, March 18th. UBS Group cut their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research note on Tuesday. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences has an average rating of “Buy” and an average price target of $52.33.

Harmony Biosciences Trading Down 0.1 %

NASDAQ:HRMY opened at $34.05 on Friday. Harmony Biosciences has a 12 month low of $26.47 and a 12 month high of $41.61. The business’s 50-day moving average is $31.38 and its two-hundred day moving average is $34.01. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm has a market capitalization of $1.96 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Hedge Funds Weigh In On Harmony Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of HRMY. Hillsdale Investment Management Inc. raised its holdings in shares of Harmony Biosciences by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock valued at $2,340,000 after buying an additional 300 shares during the last quarter. Aurora Investment Counsel increased its holdings in shares of Harmony Biosciences by 0.6% during the first quarter. Aurora Investment Counsel now owns 61,667 shares of the company’s stock valued at $2,047,000 after purchasing an additional 374 shares during the period. O Shaughnessy Asset Management LLC lifted its holdings in Harmony Biosciences by 2.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock worth $704,000 after purchasing an additional 420 shares during the period. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after buying an additional 436 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Harmony Biosciences by 0.4% in the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company’s stock worth $3,620,000 after acquiring an additional 485 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.